INSIGHT SPONSOR
We are grateful for the support of our Sponsors Genentech, The National Institutes of Health and JDRF. As always, Nature carries sole responsibility for all editorial content.
Top of pageCorporate Sponsor: Pfizer
Pfizer's search for new treatments spans hundreds of research projects across eleven major therapeutic areas- more than any other company. Of these, our commitment to improving the lives of cancer patients is particularly noteworthy. Our scientists, clinicians and other professionals employ state-of-the-art tools ranging from robotic high-throughput screening (a method pioneered by Pfizer) to sophisticated genomic studies, resulting in a steady stream of innovative new products that enhance human and animal health. Links with more than 250 partners in academia and industry further strengthen our position on the cutting edge of science and biotechnology by providing access to novel R&D tools and to key insights into the molecular basis for disease. For more information please go to www.pfizer.com
Corporate Sponsor: Genentech
For nearly 30 years, the name Genentech has been synonymous with high-quality, innovative science. The company's emphasis on strong, visionary research combined with an applied, creative focus on unmet medical needs has been instrumental to transforming care for certain patients.
Discovery research at Genentech focuses primarily on three areas of medicine: oncology, immunological disease, and disorders of tissue growth and repair, with a major focus on angiogenic disorders. Genentech scientists are at the forefront of angiogenesis research in their efforts to develop a new generation of cancer therapies, as well as a therapeutic antibody currently being studied in wet age-related macular degeneration, the leading form of age-related blindness in the world. Ongoing study into angiogenesis suggests potential therapeutic implications not only for cancer and blindness, but possibly for heart disease and wound-healing as well.
Genentech's scientists and medical professionals strive to translate basic science into patient benefit. Our experience in developing multiple protein-based products into therapeutics for serious or life-threatening medical conditions, along with our diversity and dedication to research may position Genentech to continue playing a significant role in discovering new treatments.
At Genentech, we are in business for life.
For more information on Genentech's research in these areas, please visit www.gene.com
